<DOC>
	<DOCNO>NCT02145364</DOCNO>
	<brief_summary>This prospective , multi-site trial conduct 2 clinical site . Up 20 subject receive study treatment . Following study treatment , follow-up visit occur 60 , 90 180 day subject 's last study treatment .</brief_summary>
	<brief_title>Ultherapy® Treatment Acne Scars</brief_title>
	<detailed_description>Subjects moderate severe atrophic acne scar enrol . Subjects receive three dual-depth treatment cheek temple area impact acne scar , treat number treatment square necessary cover area scar . Each treatment square receive 30 line per transducer depth total 60 line per treatment square . Three treatment 30 day apart require .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>Male female , age 18 70 year . Subject good health . Presence moderate severe atrophic acne scar cheek and/or temple . Scars must roll boxcar type scar predominantly , icepick scar present . Scars distensible tension apply skin . Subject must desire correction his/her acne scar demonstrate level dissatisfaction baseline PSQ . Subjects Fitzpatrick skin type eligible . Subject must willing withhold additional aesthetic therapy area treat entire study duration treatment judge investigator potentially impact result . Willingness ability comply protocol requirement , include return followup visit Willingness maintain current skin care regimen refrain add new product drug acne acne scar duration study . Subjects childbearing potential must negative urine pregnancy test result must lactate Screening Visit willing able use acceptable method birth control study . Absence physical psychological condition unacceptable investigator . Willingness ability provide write consent studyrequired photography adherence photography procedure . Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure . Presence active systemic local skin disease may affect wound healing . Severe solar elastosis . Recent history significant trauma face ( &lt; 6 month ) . Significant scarring , acne scar area ( ) treat . Open wound lesion area ( ) treat . Severe cystic active clinically significant acne area ( ) treat . Have recent current history inflammatory skin disease , infection , cancerous/precancerous lesion , unhealed wound propose treatment area . Have history systemic granulomatous disease active inactive connective tissue disease . Have hypertrophic acne scar , evidence keloid scarring , predominantly icepick scarring ( define half scar area either leave right treatment area ) sinus tract scar . Presence metal stent implant area ( ) treat . Inability understand protocol give inform consent . Microdermabrasion glycolic acid peel treatment area ( ) within four week prior study participation study . History allergic reaction Ibuprofen , Acetaminophen , Lidocaine/Tetracaine . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . Subjects anticipate need surgery overnight hospitalization study . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment , participate within past 30 day , study involve use investigational device drug . Current smoker history smoke last two year . History follow cosmetic treatment area treat : 1 . Skin tighten procedure within past year ; 2 . Injectable filler type within past : . 12 month Hyaluronic acid filler ( e.g. , Restylane ) ; ii . 12 month Ca Hydroxyapatite filler ( e.g. , Radiesse ) ; iii . 24 month PolyLLactic acid filler ( e.g. , Sculptra ) ; iv . Cultured fibroblast ( e.g . LaViv ) within past two year ; v. Ever permanent filler ( e.g. , Silicone , ArteFill ) 3 . Neurotoxins within past three month ; 4 . Ablative resurface laser treatment within past two year ; 5 . Nonablative , rejuvenative laser light treatment within past six month ; 6 . Surgical dermabrasion deep facial peel within past two year ; 7 . Any history contour thread . History use follow prescription medication 1 . Accutane systemic retinoids within past six month ; 2 . Topical retinoids within past two week ; 3 . Antiplatelet agent / Anticoagulants ( Coumadin , Heparin , Plavix , chronic NSAID use ) ; 4 . Aspirin great 82mg/day 5 . Psychiatric drug investigator opinion would impair subject understand protocol requirement understand signing informed consent affect ability accurately complete QOL subjective improvement assessment . Any condition opinion investigator make patient unable complete study per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Ulthera System®</keyword>
	<keyword>Ultherapy®</keyword>
	<keyword>Ulthera , Inc .</keyword>
</DOC>